secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0000950170-23-058996
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Phase 3 GLOW NPDR study meets primary endpoint; plans to resume tarcocimab
--------------------------------------------------------------------------------

- GLOW met primary endpoint: 41.1% vs 1.4% achieved >=2-step DRSS improvement (p<0.0001).
- Sight-threatening complications risk reduced 89%: 2.3% vs 21.0% (p<0.0001).
- DME development risk reduced 95%: 0.7% tarcocimab vs 13.7% sham.
- Kodiak pauses then resumes tarcocimab; plans one additional pivotal study for single BLA for wAMD, RVO, NPDR.
- Serious ocular adverse events and intraocular inflammation rates similar between groups.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017023058996/0000950170-23-058996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017023058996/kod-20231106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-058996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer